Singapore markets open in 7 hours 17 minutes

CStone Pharmaceuticals (2616.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
1.610+0.060 (+3.87%)
At close: 04:08PM HKT

CStone Pharmaceuticals

C1 Building
218 Xinghu Street North Block Suzhou Industrial Park
Suzhou 215123
China
86 512 8718 6550
https://www.cstonepharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees474

Key executives

NameTitlePayExercisedYear born
Dr. Jianxin Yang M.D., Ph.D.CEO, Senior VP & Chief Medical Officer2.76MN/A1964
Mr. Jun ChengVice President of FinanceN/AN/A1980
Dr. Ngai Chiu Tse M.D., Ph.D.Senior VP & Chief Scientific OfficerN/AN/A1967
Mr. Michael J. Choi M.B.A.Chief Commercial Officer & Chief Strategy OfficerN/AN/A1975
Ms. Yin Kwan HoJoint Company SecretaryN/AN/A1977
Ms. Weicong NiJoint Company SecretaryN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.

Corporate governance

CStone Pharmaceuticals’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.